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Many institutions have adopted algorithms based on preapheresis circulating CD34þ cell counts to optimize
the use of plerixafor. However, a circulating peripheral blood CD34þ cell threshold that predicts mobilization
failure has not been deﬁned. The superiority of plerixafor þ granulocyte colony-stimulating factor (G-CSF)
over placebo þ G-CSF for hematopoietic stem cell mobilization and collection was shown for patients with
non-Hodgkin lymphoma in a phase III, prospective, randomized, controlled study. The question remains as to
which patients may beneﬁt most from the use of plerixafor. In this post hoc retrospective analysis, mobili-
zation outcomes were compared between the 2 treatment arms in patients stratiﬁed by peripheral blood
CD34þ cell count (<5, 5 to 9, 10 to 14, 15 to 19, or 20 cells/mL) obtained before study treatment and
apheresis. Compared with placebo plus G-CSF, plerixafor plus G-CSF signiﬁcantly increased the peripheral
blood CD34þ cells/mL over prior day levels in all 5 stratiﬁed groups. The probability of subsequent trans-
plantation without a rescue mobilization was far greater in the plerixafor-treated patients for the lowest
initial (day 4) peripheral blood CD34þ cells/mL groups (<5, 5 to 9, or 10 to 14). Engraftment and durability
were the same for the 2 treatment groups for all strata, but the effect in the lower strata could be altered by
the addition of cells from rescue mobilizations. These ﬁndings may provide insight into the optimal use of
plerixafor in all patients undergoing stem cell mobilization.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous stem
cell transplantation (ASCT) can elicit long-term remission in
patients with chemotherapy-sensitive, relapsed, aggressive
non-Hodgkin lymphoma (NHL) [1]. A key requirement for
successful ASCT is the successful collection and cryopreser-
vation of hematopoietic stem cells (HSCs) with a well-
accepted minimum target number of 2  106 CD34þ
cells/kg. Retrospective analyses have reported rates of
mobilization failure in patients with NHL from approxi-
mately 20% to 30% with cytokines, either alone or in
combination with chemotherapy [2-4]. Patients who are
unable to collect this minimum number of HSCs often cannot
proceed to ASCT [5].
One assay used to screen for poor mobilizers is ﬂow
cytometric peripheral blood CD34þ enumeration. The
number of circulating CD34þ cells measured beforeedgments on page 674.
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with stem cell yields in patients with hematologic malig-
nancies. In published clinical studies, patients with pre-
apheresis CD34þ cell counts above a threshold level, ranging
from 5 to 34 CD34þ cells/mL, had signiﬁcantly greater stem
cell yields than those patients with lower preapheresis cell
counts [6-8]. To date, however, the optimal preapheresis
CD34þ cell count to predict mobilization success has not
been determined, and there is no consensus on the pre-
apheresis CD34þ threshold level that should be used to
identify patients at risk for failed collection [6-8].
Plerixafor is a ﬁrst-in-class agent currently approved in
the United States, in combination with granulocyte colony-
stimulating factor (G-CSF), to mobilize HSCs in patients
with NHL or multiple myeloma [9-11]. Plerixafor is an
inhibitor of the CXCR4 chemokine receptor that blocks
receptor binding of the stromal cellederived factor-1a [12].
Disruption of the stromal cellederived factor-1aeCXCR4
interaction contributes to the release and trafﬁcking of
stem cells from the bone marrow into the peripheral blood
and results in elevated levels of circulating HSCs both in
humans and in animal models [13,14].
The efﬁcacy and safety of plerixafor þ G-CSF in mobilizing
stem cells in patients with NHL has been established in
a phase III study (study 3101) [10]. Plerixafor þ G-CSF was
shown to signiﬁcantly increase the proportion of patients
R.T. Maziarz et al. / Biol Blood Marrow Transplant 19 (2013) 661e675 671achieving optimal (5 106) CD34þ stem cell yields for ASCT
in fewer apheresis days, compared with placeboþ G-CSF [10].
Additionally, plerixafor þ G-CSF in compassionate-use
protocols was shown to effectively salvage patients with
NHL who failed to mobilize peripheral blood stem cells
after cytokines þ chemotherapy [4,5,15,16]. Similarly, other
published studies of plerixafor in combination with
chemotherapy þ G-CSF in patients with NHL or multiple
myeloma have shown the tolerability and preliminary efﬁcacy
of such a regimen in augmenting peripheral blood CD34þ cell
count and subsequent HSC collection [17-19].
Current guidelines acknowledge the potential impact of
plerixafor on stem cell collection strategies, but debate over
its optimal use remains, as outlined in a position paper on
multiple myeloma [20]. The relatively large database from
the plerixafor licensure study [10] provides information to
assess any beneﬁt for NHL patients with various levels of
peripheral blood CD34þ cells/mL (<5, 5 to 9, 10 to 14, 15 to
19, or 20 cells/mL) after 4 days of G-CSF. The post hoc
analyses presented here were conducted to assess the
change in peripheral blood CD34þ cells/mL after addition of
plerixafor or placebo on day 4 for apheresis start on day 5
and the subsequent effect on the total number of cells
collected during apheresis and the ability of patients to
proceed to transplantation. The potential limitation of data
is that the study peripheral blood CD34þ cells/mL value was
from a central laboratory, whereas the values used for
decisions at the site were those of a local study site labora-
tory. Even so, these data may provide information about
which patients beneﬁt the most from plerixafor when G-CSF
mobilization is used for NHL patients.
METHODS
Study Design
Post hoc analyses of patients enrolled in a phase III, randomized,
double-blind, placebo-controlled study were performed to evaluate the
safety and efﬁcacy of plerixafor (.24 mg/kg s.c.) þ G-CSF (10 mg/kg/day s.c.)
versus placebo þ G-CSF in mobilizing CD34þ cells in patients with NHL
[10]. Patients were stratiﬁed by threshold levels of peripheral blood
CD34þ cells: <5, 5 to 9, 10 to 14, 15 to 19, or 20 CD34þ cells/mL, as
measured on themorning of day 4, before the ﬁrst plerixafor/placebo dose.
The increase in peripheral blood CD34þ cells on day 5, the apheresis
yields, the number of patients proceeding to transplantation, time to
engraftment, and graft durability were compared between the plerixafor
and placebo groups for patients with different thresholds of peripheral
blood CD34þ cells/mL.
Patient Eligibility
Patient eligibility followed guidelines of the previously published 3101
study [10]. Key inclusion criteria were as follows: ﬁrst or second complete
or partial response to prior therapy, last cycle of chemotherapy completed
4 weeks before enrollment, Eastern Cooperative Oncology Group
performance score of 0 or 1, white blood cell count >2.5  109 cells/L,
absolute neutrophil count >1.5  109 cells/L, platelet count >100  109
cells/L, serum creatinine 2.2 mg/dL, and liver function tests <2.5  upper
limit of normal. Patients were not eligible if they had failed previous stem
cell collection attempts, had prior stem cell transplantation, had received
G-CSF within 14 days of the ﬁrst dose of G-CSF on study, had >20% bone
marrow involvement, or had received prior radioimmunotherapy. Patients
who had their peripheral blood CD34þ cell counts measured on day 4,
before apheresis, were included in these post hoc analyses [10].
Mobilization and Transplantation
Patients received G-CSF (10 mg/kg) s.c. daily for up to 8 days, given in
the morning following the protocol-directed timing of administration.
Starting on the evening of day 4 and continuing daily for up to 4 days,
patients received either plerixafor (.24 mg/kg) or placebo s.c. Starting on
day 5, patients began daily apheresis (3.0 blood volume  10%) for up to 4
days or until sufﬁcient CD34þ cells were collected (5  106 cells/kg).
Within 5 weeks of last apheresis, patients received high-dose chemo-
therapy and underwent transplantation using collected CD34þ cellsaccording to local practice guidelines. Patients who failed to collect
either .8  106 CD34þ cells/kg after 2 days of apheresis or 2  106
CD34þ cells/kg after 4 days of apheresis were eligible to enter an open-
label rescue protocol as described previously and are included in the
analysis [10].
Determination of Hematologic Parameters for Endpoint Analysis
Peripheral blood CD34þ cell count was measured within 30 minutes
before G-CSF administration on the morning of day 4 (before plerixafor/
placebo treatment) and 10 to 11 hours after study drug treatment on the
morning of day 5. Enumeration of CD34þ cells in peripheral blood and
apheresis products was done by ﬂuorescent activated cell sorter analysis at
a local laboratory and a central laboratory (Esoterix, Inc., Austin, TX). The
local laboratory values were used for all clinical decisions. Efﬁcacy
endpoints were calculated using the percentage of CD34þ cells determined
by the central laboratory applied to the white blood cell count from the
local laboratory. Neutrophil engraftment was deﬁned as neutrophil count
.5  109/L for 3 days or 1.0  109/L for 1 day. Platelet engraftment was
deﬁned as platelet count 20  109/L without a transfusion for the
preceding 7 days.
Statistical Analysis
For continuous outcomes, P values were calculated using Wilcoxon
rank sum test. For dichotomous outcomes, P values were calculated using
chi-square test. P < .05 was considered statistically signiﬁcant, and all
analyses were performed using SAS version 8.2 or above (SAS Institute.,
Cary, NC).
RESULTS
Patients
A total of 298 patients were enrolled in the 3101 study
and randomized to receive either plerixafor þ G-CSF (n ¼
150) or placebo þ G-CSF (n ¼ 148) [10]. Day 4 peripheral
blood CD34þ cell counts were available for 132 patients
(88.0%) in the plerixafor group and for 124 patients (83.8%) in
the placebo group. Patients were stratiﬁed by threshold
levels of peripheral blood CD34þ cells:<5, 5 to 9, 10 to 14, 15
to 19, or 20 CD34þ cells/mL. Baseline characteristics and
patient demographics, by threshold group, are presented in
Table 1, including age, median time from diagnosis to
progression, median time from most recent progression to
randomization, and prior radiotherapy, and were not statis-
tically different.
Efﬁcacy
Peripheral blood CD34þ cells
Comparing plerixafor þ G-CSFetreated patients with
placebo þ G-CSFetreated patients, the median absolute
peripheral blood CD34þ cells/mL on day 4 were not signiﬁ-
cantly different between the 2 treatment arms for any of the
5 peripheral blood threshold groups (Table 2). On day 5,
however, the median absolute number of circulating
peripheral blood CD34þ cells/mL in the plerixafor-treated
group were signiﬁcantly greater compared with the
placebo-treated patients for all threshold groups (<5 cells/mL
group: 14.3 versus 3.6 cells/mL; 5 to 9 cells/mL group: 36.6
versus 11.2 cells/mL; 10 to 14 cells/mL group: 57.8 versus 18.5
cells/mL; 15 to 19 cells/mL group: 80.3 versus 23 cells/mL; 20
cells/mL group: 113.4 versus 42 cells/mL; P < .001 for all
plerixafor versus placebo comparisons in all threshold
groups) (Table 2).
CD34þ cell yields
During the ﬁrst mobilization period, the peripheral blood
stem cell collection yield was more than doubled for the
plerixafor groups in all cases when the peripheral blood
CD34þ cells/mL value was15 (Table 2). The yield was higher
for all 5 plerixafor groups. In the 3 combined groups with
15 peripheral blood CD34 cells/mL on day 4, only 12 of 93
Ta
b
le
1
Pa
ti
en
t
C
h
ar
ac
te
ri
st
ic
s,
D
em
og
ra
p
h
ic
s,
an
d
Re
le
va
n
t
C
an
ce
r
H
is
to
ry
at
B
as
el
in
e
by
Pe
ri
p
h
er
al
B
lo
od
Th
re
sh
ol
d
G
ro
u
p
Th
re
sh
ol
d
Pe
ri
p
h
er
al
B
lo
od
C
D
34
þ
C
el
ls
/m
L
on
D
ay
4
<
5
5-
9
10
-1
4
15
-1
9
2
0
Pl
ac
eb
o
þ
G
-C
SF
(n
¼
45
)
Pl
er
ix
af
or
þ
G
-C
SF
(n
¼
48
)
Pl
ac
eb
o
þ
G
-C
SF
(n
¼
28
)
Pl
er
ix
af
or
þ
G
-C
SF
(n
¼
29
)
Pl
ac
eb
o
þ
G
-C
SF
(n
¼
20
)
Pl
er
ix
af
or
þ
G
-C
SF
(n
¼1
2)
Pl
ac
eb
o
þ
G
-C
SF
(n
¼
9)
Pl
er
ix
af
or
þ
G
-C
SF
(n
¼
15
)
Pl
ac
eb
o
þ
G
-C
SF
(n
¼
22
)
Pl
er
ix
af
or
þ
G
-C
SF
(n
¼
28
)
M
ed
ia
n
ag
e
(r
an
ge
),
yr
62
(2
2-
75
)
61
(2
9-
74
)
60
(4
1-
71
)
57
(3
0-
71
)
63
(3
4-
74
)
54
(3
4-
74
)
55
(2
7-
73
)
52
(3
0-
70
)
57
(3
5-
71
)
52
(3
1-
65
)
M
ed
ia
n
ti
m
e
fr
om
d
ia
gn
os
is
to
ra
n
d
om
iz
at
io
n
(r
an
ge
),
m
o
13
(4
-9
5)
24
(4
-1
36
)
15
(4
-1
15
)
16
(4
-1
20
)
10
(4
-6
0)
7
(4
-6
0)
16
(5
-8
7)
11
(4
-8
3)
14
(3
-1
51
)
7
(4
-5
9)
M
ed
ia
n
ti
m
e
fr
om
m
os
t
re
ce
n
t
p
ro
gr
es
si
on
/r
el
ap
se
to
ra
n
d
om
iz
at
io
n
(r
an
ge
),
m
o
5
(2
-1
6)
4
(3
-1
4)
3
(0
-2
5)
4
(2
-1
9)
4
(2
-6
)
4
(3
-5
)
3
(2
-6
)
4
(2
-1
8)
4
(2
-1
1)
4
(2
-7
)
Pr
io
r
ra
d
io
th
er
ap
y,
n
(%
)
Y
es
10
(2
2.
2)
14
(2
9.
2)
7
(2
5.
0)
4
(1
3.
8)
4
(2
1.
0)
2
(1
6.
7)
3
(3
3.
3)
2
(1
3.
3)
1
(4
.6
)
2
(7
.1
)
N
o
35
(7
7.
8)
34
(7
0.
8)
21
(7
5.
0)
25
(8
6.
2)
15
(7
9.
0)
10
(8
3.
3)
6
(6
6.
7)
13
(8
6.
7)
21
(9
5.
4)
26
(9
2.
9)
R.T. Maziarz et al. / Biol Blood Marrow Transplant 19 (2013) 661e675672patients (13%) achieved a yield of 2 106 CD34þ cells/kg in 1
day in the placebo group, whereas 34 of 89 (38.2%) did so in
the plerixafor group [21] (data not shown). No patient in
a placebo group achieved 5  106 CD34þcells/kg on day 1
except in the 20 group, where 6 of 22 patients (27%)
reached this level (compared with 10/28 [36%]) in the cor-
responding plerixafor group [21] (data not shown).
In the plerixafor groups with <20 CD34þ cells, 19 of
104 reached 5  106 CD34þ cells/kg in 1 day. At the lowest
value of peripheral blood CD34þ cell/mL (<5), few patients
in the placebo group collected 2  106 CD34þ cells/kg,
whereas most of the plerixafor group did. When evaluating
the group with <5 CD34þcells/mL for the effect of plerixafor
on the number of apheresis required to collect cells, the
effect was very different from the placebo group. By day of
apheresis the median collection (CD34þ cells  106/kg) for
plerixafor versus placebo was day 1: 1.00 versus .40,
P < .001; day 2: 2.17 versus .70, P < .001; and day 4: 3.31
versus .78, P < .001. When the CD34þ cells/mL value was at
least 15 by day 4 of G-CSF, all patients in both groups could
collect 2  106 CD34þ cells/kg.
Table 3 shows the apheresis yields for the placebo group
and the plerixafor group separated into the 5 categories of
peripheral blood CD34þcells/mL on day 4 (before either
placebo or plerixafor dose). The collection of <1, 1 to <2, 2 to
<5, and 5  10 6 cells/kg is shown for the total apheresis
period which could be 1 to 4 days (see Methods). These data
show that (per the central reference laboratory) at least
a peripheral blood count of 15 CD34þcells/mL was needed so
that almost all patients collect 2  106 CD34þ cells/kg. The
likelihood of collecting 5  106 CD34þ cells/kg is enhanced
with at least a peripheral blood count of 20 CD34þ cells/mL.
Transplantation and engraftment
In Table 2, the number of cells infused for transplantation
is given for each group of patients listed by initial peripheral
blood CD34þ cells/mL value at day 4. However, the total is
either that obtained during the ﬁrst mobilization period only
or a combination of cells from the ﬁrst mobilization period
plus the trial mandated rescue mobilization period. Those
patients undergoing rescue are listed in the last horizontal
row in the Table 2. Therefore, in the predicted worst patients
to mobilize (<5 CD34þ cells/mL on day 4), some of the
plerixafor-treated patients (14/48; 29%) were not mobilized
during the ﬁrst mobilization period, whereas most of the
placebo-treated patients (36/45; 80%) failed. When those
failing to mobilize during the ﬁrst mobilization period were
then mobilized with G-CSF þ plerixafor and the combined
yields were used for transplantation, the majority of both
groups were transplanted. The 2 groups with peripheral
blood CD34þ cells/mL values of<5 and 5 to 9 were mobilized
at day 4, and there were fewer requiring rescue: in the
plerixafor group (6/77; 8%) and in the placebo group (32/73;
44%). When the peripheral blood CD34þ cell/ul mL value was
10 to 14 in the placebo group, 25% (5/20) still needed rescue.
Engraftment
Postautologous HSCT, the median engraftment for every
group for platelets was between 19 and 21 days and for
neutrophils was 10 or 11 days (data not shown). All patients
in both groups had durable grafts at 1 year, with the excep-
tion of 2 patients in the plerixafor arm (1 with <5 cells/mL
and 1 with 20 cells/mL); as previously reported, 1 patient
had myelodysplastic syndrome and the other remained
clinically stable at the 18-month follow-up [10].
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The goal of these post hoc analyses was to explore the
efﬁcacy of plerixafor in augmenting stem cell collection in
patients with NHL across varying preapheresis circulating
CD34þ cell thresholds. This task was facilitated by availing
ourselves of two matched patient cohorts from the phase III
randomized 3101 trial [10]. By stratifying patients in these
analyses according to preapheresis levels of peripheral blood
CD34þ cells, we hoped to understand the impact of plerix-
afor use on mobilization yields in patients with varying
preapheresis CD34þ cell counts.
A positive effect of plerixafor on stem cell collection was
observed across all peripheral blood CD34þ threshold
groups, including the group with a preapheresis CD34þ cell
count <20 cells/mL, composed of patients generally consid-
ered to be “slow” or “poor” mobilizers. Although there is no
consensus on the preapheresis CD34þ threshold level that
should be used to identify patients at risk for poor mobili-
zation, previous studies have shown that patients with pre-
apheresis CD34þ cell counts 20 cells/mL were signiﬁcantly
more readilymobilizedwith G-CSF chemotherapy and able
to collect sufﬁcient HSCs for ASCT than were patients with
cell counts <20 cells/mL [8,22]. If one accepts this level as
“standard,” then 80% of the patients included in this analysis
of the 3101 study were considered at risk for poor mobili-
zation, recognizing that >50% of patients treated with
G-CSF þ placebo had CD34þ progenitors of <10/mL on day 4
(Table 2). In our analysis, the median cumulative stem cell
yield in patients with a preapheresis cell count <20 cells/mL
treated with placebo þ G-CSF did not reach minimum
collection targets, even after 4 days of apheresis, requiring
that these patients underwent a second mobilization
procedure, to pursue ASCT.
Treatment with plerixafor þ G-CSF signiﬁcantly rescued
these patients with low cell counts, providing strong support
that the upfront use of plerixafor could beneﬁt patients with
preapheresis CD34þ cell counts <20 cells/mL who do not
mobilize sufﬁciently with G-CSF alone (approximately 40% of
cases), particularly in the setting where G-CSF is dosed by
U.S. Food and Drug Administration label standards rather
than at higher doses, as some single institutional studies
have reported [23]. In particular, our analysis carries rele-
vance for patients with preapheresis peripheral blood
CD34þ cell counts <5 cells/mL who are consistently
precluded from apheresis based on their low cell counts.
Treatment with plerixaforþ G-CSF allowedmore than 70% of
these patients to reach minimum stem cell collection targets.
The obvious question is what is the “low” peripheral
blood CD34þ cells/mL value that provides the most beneﬁt of
all for the use of plerixafor? Every patient in both groups
with a CD34þ cell/mL value of  20 was able to be mobilized
for transplantation. The only potential beneﬁt of plerixafor
was to use it in fewer apheresis procedures or to mobilize
more cells [10]. Other potential reasons to use plerixafor at
this level of CD34þ cells/mL include presentation of risk
factors for poor mobilization (age, prior chemotherapy, prior
ﬂudarabine or lenalidomide exposure, etc.) and the need for
predictable cell collection. Patients with 15 to 19 CD34þ
cells/mL likewise all mobilized at 2  106 CD34þ cells/kg.
However, when there were <15 CD34þ cells/mL, 25% or more
of patients who did not receive plerixafor failed to mobilize
and collect enough cells for transplantation. At <5 CD34þ
cells /mL, G-CSF alone was clearly unacceptable without
a subsequent rescue mobilization in these NHL patients. At
the same level of CD34þ cells/mL, plerixafor þ G-CSF was
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R.T. Maziarz et al. / Biol Blood Marrow Transplant 19 (2013) 661e675674successful in 34 of 48 patients (71%). Thus, in the predicted
worst patients, G-CSF þ plerixafor can be a viable means to
mobilize peripheral blood stem cell in NHL patients, espe-
cially when chemomobilization may not be appropriate.
Although it is current standard practice for stem cell
transplant centers to determine CD34þ cell counts before
apheresis, one must recognize the potential variability in
these assays. There can be center-to-center variability in the
preapheresis cell count threshold used to predict collection
failure. Precollection CD34þ enumeration is more predictive
after G-CSF þ chemotherapy mobilization compared with
G-CSF alone, because CD34þ cells can be counted more
accurately with a lower coefﬁcient of variability in the
background of low circulating leukocytes after G-CSF þ
chemotherapy than in the background of high circulating
leukocytes after G-CSF alone [24]. As a result, some centers
will dilute the circulating white blood count in this setting to
normalize the collection. Furthermore, the variability that
arises from differing cell quantiﬁcation methods effectively
precludes cross-study comparisons that may allow clinical
validation of a speciﬁc cell count threshold as a predictor of
mobilization success [25].
We recognize that individual institutions set their own
algorithms for utilization of preapheresis CD34þ cell count
to guide the apheresis decision; however, given the potential
variability, such algorithms need to be prospectively and
institutionally validated. Continued clariﬁcation of this issue
of CD34þ cell count assessment is a necessary hurdle toward
the goal of developing standard treatment guidelines out-
lining the optimal use of plerixafor in patients with NHL and
other hematologic malignancies. To this end, our ﬁndings
provide signiﬁcant insight into the speciﬁc patient pop-
ulation that may derive the greatest beneﬁt from plerixafor
treatment, an important step toward deﬁning the optimal
use of this drug.
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